The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga.
The recreational side of cannabis may be generating more buzz of late (thanks in part to increasing sales), but investors shouldn’t forget about the medical cannabis market.
Thanks to earlier legalization, the medical cannabis market remains the more mature side of the industry. Medical marijuana is at least partially legal in 39 states as of July 2020 (though Virginia, Texas, Kentucky, Iowa, Indiana, and Georgia only allow use of CBD oil for medicinal purposes), while only 11 states and the District of Columbia have legalized recreational cannabis as well.
And unlike recreational cannabis, which is limited to the same half dozen stable of product categories, new use cases for medical cannabis are still being discovered. As of March, the FDA had approved one cannabis-derived and three cannabis-related drug products, though that number will surely grow.
In addition to pharmaceuticals being developed, when you factor in the use of CBD (the non-psychoactive part of the cannabis plant), the medical marijuana market gets even larger. Though it’s important to remember that CBD products are not regulated by the FDA and therefore cannot make specific health claims, the industry is still predicted to grow substantially.
Investment firm Cowen & Co. estimated in March that the U.S. CBD market could generate as much as $16 billion in revenue by 2025 (compared to approximately $1 billion in 2019).
The topic of CBD is the subject of the CBD Biopharma Investor Conference, a virtual investor conference hosted by OTC Markets on Thursday. Executives from six CBD companies will provide investors with updates on their latest products and financials.
Here’s the full schedule of Thursday’s presenters. Each presentation is also available on demand.
10:30 AM ET Avicanna Inc. AVCNFAVCN
Speaker: Aras Azadian, Chief Executive Officer, Co-Founder
11:00 AM ET Cardiol Therapeutics Inc. CRTPFCRDL
Speaker: David Elsley, President and CEO
11:30 AM ET Medipharm Labs Corp. MEDIFLABSMLZ)
Speakers: Pat McCutcheon, CEO & Chairman of the Board; Laura Lepore, Vice President, Investor Relations & Communications
12:00 PM ET Willow Biosciences Inc. CANSFWLLW
Speaker: Trevor Peters, President & CEO
12:30 PM ET Marijuana Company of America, Inc. MCOA
Speakers: Jesus Quintero, Chairman of the Board of Directors, CEO & CFO; Gloria Albarran Lynch, Chief Marketing Officer; Robert L Hymers, Strategic Advisory Board for MCOA
1:00 PM ET FinCanna Capital Corp. FNNZFCALI
Speaker: Andriyko Herchak, CEO & Director
To attend today’s conference, click here.
Image source: www.chemist-4-u.com
The preceding post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Although the piece is not and should not be construed as editorial content, the sponsored content team works to ensure that any and all information contained within is true and accurate to the best of their knowledge and research. This content is for informational purposes only and not intended to be investing advice.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving – don’t get left behind!
Curious about what’s next for the industry and how to leverage California’s unique market?
Join top executives, policymakers, and investors at the Benzinga Cannabis Market Spotlight in Anaheim, CA, at the House of Blues on November 12. Dive deep into the latest strategies, investment trends, and brand insights that are shaping the future of cannabis!
Get your tickets now to secure your spot and avoid last-minute price hikes.